PDB Short entry for 1GOE HEADER HORMONE 20-OCT-01 1GOE TITLE MONITORING THE STRUCTURAL CONSEQUENCES OF PHE12-->D-PHE12 TITLE 2 AND LEU15-->AIB15 SUBSTITUTION IN H/R CORTICOTROPIN TITLE 3 RELEASING HORMONE: IMPLICATIONS FOR DESIGN OF CRH TITLE 4 ANTAGONISTS. COMPND MOL_ID: 1; COMPND 2 MOLECULE: CORTICOTROPIN RELEASING HORMONE; COMPND 3 CHAIN: A; COMPND 4 MUTATION: YES; COMPND 5 OTHER_DETAILS: SYNTHETIC ANALOGUE WITH ISOLEUCINE-AMIDE COMPND 6 C-TERMINUS SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 4 ORGANISM_COMMON: HUMAN; SOURCE 5 ORGANISM_TAXID: 9606; SOURCE 6 OTHER_DETAILS: SYNTHETIC ANALOGUE SYNTHESIZED THROUGH SOURCE 7 SOLID PHASE SYNTHESIS USING FMOC/TBU SYNTHETIC PROTOCOLS. SOURCE 8 NATIVE PHE12 AND LEU15 HAS BEEN SUBSTITUTED BY D-PHE AND SOURCE 9 ALPHA-AMINOISOBUTYRIC ACID KEYWDS HORMONE, CORTICOTROPIN RELEASING HORMONE, SYNTHETIC KEYWDS 2 ANALOGUES, SOLID PHASE SYNTHESIS, NMR, SOLUTIONS STRUCTURE EXPDTA SOLUTION NMR NUMMDL 40 AUTHOR G.A.SPYROULIAS,S.PAPAZACHARIAS,G.PAIRAS,P.CORDOPATIS REVDAT 4 21-OCT-15 1GOE 1 SOURCE REMARK VERSN DBREF REVDAT 4 2 SEQADV REVDAT 3 24-FEB-09 1GOE 1 VERSN REVDAT 2 12-DEC-02 1GOE 1 JRNL REVDAT 1 31-OCT-01 1GOE 0 JRNL AUTH G.A.SPYROULIAS,S.PAPAZACHARIAS,G.PAIRAS, JRNL AUTH 2 P.CORDOPATIS JRNL TITL MONITORING THE STRUCTURAL CONSEQUENCES OF JRNL TITL 2 PHE12-->D-PHE AND LEU15-->AIB SUBSTITUTION IN JRNL TITL 3 HUMAN/RAT CORTICOTROPIN RELEASING HORMONE JRNL REF EUR.J.BIOCHEM. V. 269 6009 2002 JRNL REFN ISSN 0014-2956 JRNL PMID 12473096 JRNL DOI 10.1046/J.1432-1033.2002.03278.X REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH C.ROMIER,J.M.BERNASSAU,C.CAMBILLAU,H.DARBON REMARK 1 TITL SOLUTION STRUCTURE OF HUMAN CORTICOTROPIN REMARK 1 TITL 2 RELEASING FACTOR BY 1H NMR AND DISTANCE GEOMETRY REMARK 1 TITL 3 WITH RESTRAINED MOLECULAR DYNAMICS. REMARK 1 REF PROTEIN ENG. V. 6 149 1993 REMARK 1 REFN ISSN 0269-2139 REMARK 1 PMID 8386360 REMARK 1 DOI 10.1093/PROTEIN/6.2.149 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : AMBER 5.0 REMARK 3 AUTHORS : PETER KOLLMAN, DAVE CASE, KEN MERZ, THOMAS REMARK 3 CHEATHAM, CARLOS SIMMERLING, TOM DARDEN REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT DETAILS CAN BE FOUND IN REMARK 3 THE JRNL CITATION ABOVE. REMARK 4 REMARK 4 1GOE COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 22-OCT-01. REMARK 100 THE PDBE ID CODE IS EBI-8730. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 310 REMARK 210 PH : 3.8 REMARK 210 IONIC STRENGTH : NULL REMARK 210 PRESSURE : 1 ATM REMARK 210 SAMPLE CONTENTS : 34% H2O / 66% TFE REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : COSY; TOCSY; NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ REMARK 210 SPECTROMETER MODEL : AMX600 REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : DYANA AND AMBER REMARK 210 METHOD USED : HYBRID DISTANCE GEOMETRY REMARK 210 SIMULATED ANNEALING IN TORSION REMARK 210 ANGLE SPACE REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 400 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 40 REMARK 210 CONFORMERS, SELECTION CRITERIA : LEAST RESTRAINT VIOLATION REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 20 REMARK 210 REMARK 210 REMARK: THE STRUCTURE WAS DETERMINED USING 1H-1H REMARK 210 DOUBLE-RESONANCE NMR SPECTROSCOPY. NMR-DERRIVED DISTANCE REMARK 210 RESTRAINTS AND 3JHAHN COUPLING CONSTANTS AS WELL AS REMARK 210 H-BOND CONSTRAINTS USED IN STRUCTURAL CALCULATION AND REMARK 210 REFIMENT PROCEEDURE. REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 GLU A 2 -56.61 -153.03 REMARK 500 1 GLU A 17 -61.26 -121.41 REMARK 500 2 GLU A 2 -63.41 -143.62 REMARK 500 2 GLU A 17 -61.25 -122.80 REMARK 500 3 GLU A 2 -71.68 -155.01 REMARK 500 3 GLU A 17 -61.54 -122.37 REMARK 500 4 ARG A 16 4.76 -69.85 REMARK 500 5 GLU A 17 -63.95 -92.78 REMARK 500 6 GLU A 17 -63.71 -126.30 REMARK 500 7 GLU A 17 -65.75 -99.52 REMARK 500 10 GLU A 2 -50.67 -152.96 REMARK 500 13 GLU A 2 -85.65 -83.40 REMARK 500 13 GLU A 17 -61.78 -109.68 REMARK 500 16 GLU A 17 -62.54 -120.05 REMARK 500 17 GLU A 17 -60.22 -123.58 REMARK 500 18 GLU A 2 -53.60 -137.30 REMARK 500 20 GLU A 17 -62.47 -121.28 REMARK 500 21 GLU A 17 -64.06 -102.51 REMARK 500 22 GLU A 17 -64.47 -121.72 REMARK 500 28 LEU A 19 -46.27 -132.20 REMARK 500 31 GLU A 2 -59.98 -125.90 REMARK 500 32 GLU A 2 15.36 -141.41 REMARK 500 32 ARG A 16 1.68 -68.23 REMARK 500 34 GLU A 17 -65.30 -121.07 REMARK 500 36 GLU A 3 -61.16 -100.07 REMARK 500 38 GLU A 17 -62.22 -121.83 REMARK 500 39 ARG A 16 21.14 -77.78 REMARK 500 39 GLU A 17 -62.72 -124.64 REMARK 500 40 GLU A 17 -63.85 -125.33 REMARK 500 REMARK 500 REMARK: NULL REMARK 615 REMARK 615 ZERO OCCUPANCY ATOM REMARK 615 THE FOLLOWING RESIDUES HAVE ATOMS MODELED WITH ZERO REMARK 615 OCCUPANCY. THE LOCATION AND PROPERTIES OF THESE ATOMS REMARK 615 MAY NOT BE RELIABLE. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 615 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 615 M RES C SSEQI REMARK 615 NH2 A 42 DBREF 1GOE A 1 41 UNP P06850 CRF_HUMAN 154 194 SEQADV 1GOE DPN A 12 UNP P06850 PHE 165 ENGINEERED MUTATION SEQADV 1GOE AIB A 15 UNP P06850 LEU 168 ENGINEERED MUTATION SEQADV 1GOE NH2 A 42 UNP P06850 AMIDATION SEQRES 1 A 42 SER GLU GLU PRO PRO ILE SER LEU ASP LEU THR DPN HIS SEQRES 2 A 42 LEU AIB ARG GLU VAL LEU GLU MET ALA ARG ALA GLU GLN SEQRES 3 A 42 LEU ALA GLN GLN ALA HIS SER ASN ARG LYS LEU MET GLU SEQRES 4 A 42 ILE ILE NH2 HET DPN A 12 20 HET AIB A 15 13 HET NH2 A 42 3 HETNAM DPN D-PHENYLALANINE HETNAM AIB ALPHA-AMINOISOBUTYRIC ACID HETNAM NH2 AMINO GROUP FORMUL 1 DPN C9 H11 N O2 FORMUL 1 AIB C4 H9 N O2 FORMUL 2 NH2 H2 N HELIX 1 1 ILE A 6 VAL A 18 1 13 HELIX 2 2 GLU A 20 ILE A 40 1 21 LINK C THR A 11 N DPN A 12 1555 1555 1.34 LINK C DPN A 12 N HIS A 13 1555 1555 1.33 LINK C LEU A 14 N AIB A 15 1555 1555 1.34 LINK C AIB A 15 N ARG A 16 1555 1555 1.34 LINK C ILE A 41 N NH2 A 42 1555 1555 1.33 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000